Division of Gastroenterology, Department of Medicine, University of Alberta , Edmonton, Canada.
Expert Rev Gastroenterol Hepatol. 2020 Jun;14(6):405-410. doi: 10.1080/17474124.2020.1764349. Epub 2020 May 20.
Perianal fistulizing Crohn's disease is associated with a poor quality of life and current medical and surgical treatment options are limited. Darvadstrocel, composed of mesenchymal stem (stromal) cells (MSC), has recently been approved by the European Medicines Agency (EMA) for the treatment for perianal disease. This drug profile educates the reader with this novel treatment approach.
A literature search was performed on PubMed with focus on perianal fistulizing Crohn's disease and mesenchymal stem (stromal) cells. This review summarizes evidence of the current standard of care and discusses the mechanism of action, manufacturing, and application and safety of darvadstrocel.
Darvadstrocel is a safe and effective therapy for complex perianal fistulizing Crohn's disease.
肛周瘘管型克罗恩病与生活质量较差相关，目前的医学和手术治疗选择有限。达瓦达司妥昔单抗，由间充质干细胞（基质）组成，最近已被欧洲药品管理局（EMA）批准用于治疗肛周疾病。该药物简介为读者提供了这种新的治疗方法。
在 PubMed 上进行了肛周瘘管型克罗恩病和间充质干细胞（基质）的文献检索。本综述总结了目前的标准治疗方法，并讨论了达瓦达司妥昔单抗的作用机制、制造、应用和安全性。
达瓦达司妥昔单抗是治疗复杂肛周瘘管型克罗恩病的一种安全有效的疗法。
